3 tips for biotech startups seeking non-dilutive capital to survive the downturn
![](https://xn--9ckkn2541by7i2mhgnc67gnu2h.xyz/wp-content/uploads/2020/01/2020-01-19_18h38_21.png)
James Coates
Contributor
Share on Twitter
James Coates is the Health and Human Performance principal at Decisive Point, a venture capital and advisory firm that invests in and supports startups with emerging defense technologies.
Future-proofing the finances of your biotech startup through a market collapse means more than just raising capital or rushing to close your round.
I perform due diligence on dozens of life science companies each week whose technologies might help future-proof the world against the next biothreat, p
コメント